Samuel Levy
Founding Partner @ Lauxera Capital Partners
Paris, France
Samuel Levy is a Series C investor at Lauxera Capital Partners in Paris focused on Health Care and Medical Device. Samuel Levy is the Founding Partner at Lauxera Capital. He attended the Yale University.
- Total investments:
- 6
- Last investment:
- Lead investor:
- 67%
Last updated:
For AI agents: llms.txt
Industries Samuel Levy invests in
Stages Samuel Levy invests in
Countries Samuel Levy invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Health Care 4 (67%)
- Medical Device 4 (67%)
- Apps 1 (17%)
- Fitness 1 (17%)
- Medical 1 (17%)
Stage
- Series C 2 (33%)
- Private Equity 2 (33%)
- Funding Round 1 (17%)
- Venture - Series Unknown 1 (17%)
Country
- United States 2 (33%)
- Sweden 1 (17%)
- Germany 1 (17%)
- United Kingdom 1 (17%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
| Bridge to Life was founded with the mission of improving organ transplants by licensing and developing new preservation solutions and technologies to provide the highest quality of service to organ procurement organizations and transplant centers. The U.S. based company, headquartered in Northbrook, Illinois, is a leading supplier of preservationsolutions worldwide with a focus on innovation in organ preservation and machine perfusion. Through a strong focus on collaboration with surgeons and transplant professionals, it continues to explore emerging science and preservation technologies. | $110M / Series C / Aug 12, 2026 | ||
| OrganOx Limited was founded in 2008 to exploit normothermic preservation technology invented by Prof Peter Friend and colleagues and further developed by Prof Constantin Coussios at the University of Oxford. | $160M / Venture - Series Unknown / Feb 24, 2025 | ||
| Acandis GmbH offers Engineering Stroke Solutions, Flow Diverter, Stent Retriever, Embolisation Devices, Acute Stroke Care, Thrombectomy, and PTA. They provide medical devices and products for the treatment of neurovascular diseases for patients. If anyone wants to contact them please contact them via phone call or email. | $52.1M / Private Equity / Jan 22, 2025 | ||
| Acandis GmbH offers Engineering Stroke Solutions, Flow Diverter, Stent Retriever, Embolisation Devices, Acute Stroke Care, Thrombectomy, and PTA. They provide medical devices and products for the treatment of neurovascular diseases for patients. If anyone wants to contact them please contact them via phone call or email. | $52M / Jan 22, 2025 | ||
| Natural Cycles offers a contraceptive app, spearheading digital contraception, a new category in female reproductive health.Users measure their basal body temperature in the morning and the app computes the temperature (and other relevant data like levels of luteinizing hormone) through an algorithm to calculate whether they are fertile or not.Natural Cycles’ subscription product relies on an algorithmic method to predict which days women are fertile during their monthly cycle — with an in-app color-coded calendar informing users if they could have unprotected sex on a given day or not.Women using the app are required to measure and input their body temperature daily using a basal thermometer. Natural Cycles relies on this and other individual data inputs to algorithmically calculate the probability of the user being fertile on each day in her cycle. | $55M / Series C / May 29, 2024 | ||
| Veranex is the first truly end-to-end, global, tech-enabled, concept-through-commercialization service provider that focuses solely on medical technology: medical device, diagnostics, companion diagnostics, digital health, and drug delivery. For all your needs through the entire medical device clinical trial process, Veranex is transforming medtechinnovations. | Private Equity / May 19, 2022 |
Co-Investors
About Lauxera Capital Partners
Lauxera Capital Partners is an independent, international, healthcare-focused asset management company. Our growth equity investments focus primarily on commercial-stage medical devices, digital health, life sciences tools, and healthcare data companies. Led by entrepreneurial company builders and seasoned healthcare investors with experienceacross international markets, we empower European healthtech entrepreneurs to deliver the growth promised by their innovations.Lauxera was created in 2020 and has offices in Paris and San Francisco.
Lauxera Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Alex Slack
Co-Founder
|
|||
|
Samuel Levy
Founding Partner
|
|||
|
Victor Decrion
Managing Partner
|
|||
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Samuel Levy invest in?
Samuel Levy invests primarily in Health Care, Medical Device and Apps startups, most often at Series C and Private Equity stage. Most of the 6 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Samuel Levy?
Public channels for Samuel Levy include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Samuel Levy last invest?
The most recent investment recorded for Samuel Levy closed in Aug 2026. Shizune tracks 6 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Oct 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
